Navigation Links
Halozyme Therapeutics Reports First Quarter 2011 Financial Results

SAN DIEGO, May 6, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today reported financial results for the first quarter 2011.


"The faster insulin absorption and shorter duration of action observed in our first ultrafast insulin pump study is exciting," stated Gregory I. Frost, Ph.D., Halozyme's president and CEO. "Patients with diabetes that use insulin pumps could see unique benefits from Halozyme's Ultrafast Insulin."

First Quarter 2011 and Recent Business Highlights

  • Halozyme presented preliminary results from its first Ultrafast Insulin study in type 1 diabetes patients who receive their treatment with an insulin pump demonstrating that Aspart-PH20 generates a faster-in and faster-out profile with accelerated insulin absorption and a shorter duration of action compared to aspart alone. Aspart-PH20 is a formulation of Halozyme's rHuPH20 (recombinant human hyaluronidase) enzyme with the active ingredient in NovoLog® that was administered as a continuous subcutaneous insulin infusion over 72 hours with an insulin pump. Halozyme presented these results at the American Association of Clinical Endocrinologists meeting in San Diego on April 14, 2011.  
  • American Diabetes Association (ADA) 71st Scientific Sessions – June 24-28, 2011 in San Diego. Halozyme has received acceptance notification for two presentations of results from its Ultrafast Insulin studies at this year's ADA. A poster presentation examines the role that the coinjection of rHuPH20 with prandial insulin plays in the acceleration of pharmacokinetics and glucodynamics across a variety of populations. The second data set to be presented utilizes continuous glucose monitoring over a 72-hour period to test the variability of insulin absorption with and without rHuPH20 at the beginning and the end of a 12-week treatment study. The goal of Halozyme's Ultrafast Insulin program is to develop a best-in-class mealtime insulin product compared to the currently prescribed analogs that participate in the growing $3.8 billion worldwide prandial insulin market.

  • First Quarter 2011 Financial ResultsThe net loss for the first quarter of 2011 was $9.6 million, or $0.10 per share, compared with a net loss for the first quarter of 2010 of $11.8 million, or $0.13 per share.

  • Revenue for the first quarter of 2011 was $7.5 million, compared to $3.4 million for the first quarter of 2010. Revenues under collaborative agreements for the first quarter of 2011 were $7.4 million, compared to $3.0 million for the first quarter of 2010. Revenues under collaborative agreements in the first quarter of 2011 primarily consisted of a milestone payment and the amortization of upfront payments received from Baxter and Roche of $5.7 million and research and development reimbursements from Baxter and Roche of $1.6 million.
  • Research and development expenses for the first quarter of 2011 were $13.8 million, compared with $11.5 million for the first quarter of 2010, primarily due to an increase in clinical trial activities supporting the Ultrafast Insulin program.  
  • Selling, general and administrative expenses for the first quarter of 2011 were $3.4 million, compared to $3.8 million for the first quarter of 2010. The decline for SG&A results from lower compensation and market research expenses during the quarter.  
  • Cash and cash equivalents were $73.8 million as of March 31, 2011, compared with $83.3 million as of December 31, 2010 and $55.2 million as of March 31, 2010. Net cash burn for the first quarter of 2011 was approximately $9.4 million.
  • For 2011, management anticipates total operating expenses will be slightly higher than those reported for 2010, which were approximately $68 million. The increase for operating expense is expected to arise from costs associated with additional activities related to clinical trials and manufacturing. The company continues to expect net cash burn of $47 to $52 million for the year 2011.

  • Upcoming Corporate and Scientific PresentationsHalozyme representatives are scheduled to present at the following events:

  • Bank of America Merrill Lynch Health Care Conference in Las Vegas, May 12, 2011 at 11:10 a.m. PDT (2:10 p.m. EDT). To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the company's Web site at The replay will be available for six months after the event.
  • American Diabetes Association Scientific Sessions – June 24-28, 2011 in San Diego. Halozyme has been notified of acceptance for two presentations of results and data from its Ultrafast Insulin program.

  • Conference CallHalozyme management will host a conference call and webcast on May 6, 2011 to discuss these topics beginning at 8:00 a.m. PDT (11:00 a.m. EDT). To participate via telephone, please call 877.407.8037 for domestic callers or 201.689.8037 for international callers. A telephone replay will be available beginning shortly after the end of the call by dialing 877.660.6853 from the U.S. or 201.612.7415 for international callers and using account # 367 and replay ID # 371588. The conference call will be broadcast live over the Internet at and the replay will be available on the company's Web site for seven days.

    About Halozyme TherapeuticsHalozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche and with Baxter to apply Enhanze technology to biological therapeutics including Herceptin®, MabThera® and immunoglobulin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit

    Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the timing and scope of our clinical trials as well as expected activities under our collaborative partnerships) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

    Halozyme Contact
    Robert H. Uhl
    Senior Director, Investor Relations
    (858) 704-8264
    ruhl@halozyme.comHalozyme Therapeutics, Inc.Condensed Consolidated Statements of OperationsQuarters Ended March 31,20112010(unaudited)(unaudited)REVENUES:Product sales

    397,810Revenues under collaborative agreements

    7,378,4453,043,921Total revenues

    7,543,8943,441,731OPERATING EXPENSES:Cost of product sales

    11,7175,660Research and development

    13,785,79711,467,204Selling, general and administrative

    3,405,9663,757,013Total operating expenses

    17,203,48015,229,877OPERATING LOSS

    (9,659,586)(11,788,146)Interest and other income, net

    23,869669NET LOSS

    (9,635,717)$  (11,787,477)Basic and diluted net loss per share

    (0.13)Shares used in computing basic and dilutednet loss per share

    100,927,40291,610,830Halozyme Therapeutics, Inc.Condensed Consolidated Balance SheetsMarch 31, December 31,20112010(unaudited)ASSETS Current assets:Cash and cash equivalents

    83,255,848Accounts receivable


    248,474193,422Prepaid expenses and other assets.

    3,382,9933,720,896Total current assets

    79,192,09189,498,434Property and equipment, net

    1,741,1921,846,899Total Assets

    91,345,333LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

    3,820,368Accrued expenses

    8,238,2678,605,569Deferred revenue

    2,914,4792,917,129Total current liabilities

    12,603,73915,343,066Deferred revenue, net of current portion

    54,447,80355,176,422Deferred rent, net of current portion

    366,392474,389Stockholders' equity:Common stock

    102,033100,581Additional paid-in capital

    248,300,828245,502,670Accumulated deficit

    (234,887,512)(225,251,795)Total stockholders' equity.

    13,515,34920,351,456Total Liabilities and Stockholders' Equity


    SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
    2. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
    3. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
    4. Halozyme Receives $5.5 Million Payment From Baxter
    5. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
    6. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
    7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
    8. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    9. Halozyme Therapeutics to Host Research Day for Investors and Analysts
    10. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
    11. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    Post Your Comments:
    (Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... San Diego-based ... of its corporate rebranding initiative announced today. The bold new look is part ... as the company moves into a significant growth period. , It will also expand ...
    (Date:10/10/2017)... firm Parks Associates announced today that Tom Kerber , ... Meeting , October 11 in Scottsdale, Arizona . Kerber ... smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction ...
    (Date:10/9/2017)... 2017  BioTech Holdings announced today identification and ... ProCell stem cell therapy prevents limb loss in ... demonstrated that treatment with ProCell resulted in more ... compared to standard bone marrow stem cell administration.  ... reduction of therapeutic effect.  ...
    (Date:10/9/2017)... ... October 09, 2017 , ... ... medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the surface electromyography ... generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective multicenter phase ...
    Breaking Biology Technology:
    (Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
    (Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
    (Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
    Breaking Biology News(10 mins):